ALEC, a conservative legislative group that receives drug industry funding, is advocating against state 340B legislation. Provider groups have criticized the campaign and launched their own efforts in support of 340B state bills.
340B Program Critics, Supporters Target States
Views
As 340B stakeholders continue to hold out for long-awaited congressional action that could overhaul the discount drug pricing program, some [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
